Molbio Diagnostics Eyes ₹940 Crore in IPO to Fuel Expansion

Molbio Diagnostics, a leading player in the molecular diagnostics sector, is preparing to launch an initial public offering (IPO) to secure ₹940 crore. The company aims to raise ₹200 crore through a fresh issue of shares for capital expenditure and an additional ₹740 crore through an offer for sale, which will see promoter stakes reduced from 46.6% to 43%.

Global Reach and Revenue Growth

Founded in 2000, Molbio Diagnostics has established a significant global presence with six manufacturing facilities in India, serving clients in over 90 countries. The company's notable growth has been largely driven by its tuberculosis diagnostic test kits, which contribute substantially to its revenue. In fiscal year 2026, revenue from operations increased by 41.7% year-on-year, reaching ₹1,445.7 crore. The net profit for the same period rose by 18.4% to ₹164.1 crore, showcasing robust financial health.

Product Portfolio and Market Position

The company is renowned for its 'Truenat' platform, a portable diagnostic system that provides rapid and accurate test results, particularly useful in resource-limited settings. Molbio offers molecular testing solutions for over 30 diseases through 43 diagnostic assays, while also providing radiology, digital pathology, and breast health screening solutions via its subsidiaries and strategic collaborations.

Nearly 74% of Molbio's revenue is generated from the sale of test kits, with tuberculosis test kits alone accounting for 70% of this figure. The company’s reliance on government and international aid agencies is significant, as these entities contribute over four-fifths of its revenue.

Investor Considerations

For investors with a high-risk tolerance, Molbio's IPO presents an opportunity to engage with a company that is not only expanding its global footprint but also showing consistent financial growth. The company's EBITDA margin improved to 22.6% in FY26 from 22% in FY24, reflecting operational efficiency. Molbio is seeking a price-earnings (P/E) multiple of up to 57, which is competitive compared to other listed peers in the healthcare diagnostics sector, such as Dr. Lal PathLabs and Metropolis Healthcare, which have P/E multiples ranging from 54 to 81.

As Molbio Diagnostics continues to innovate and expand, the IPO could potentially offer long-term growth prospects for investors willing to navigate the inherent risks of the diagnostics market.